(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 9.07% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.3%.
Abbvie's revenue in 2026 is $61,160,000,000.On average, 34 Wall Street analysts forecast ABBV's revenue for 2026 to be $120,978,123,801,040, with the lowest ABBV revenue forecast at $115,408,391,413,240, and the highest ABBV revenue forecast at $125,379,096,471,908. On average, 33 Wall Street analysts forecast ABBV's revenue for 2027 to be $130,803,839,000,724, with the lowest ABBV revenue forecast at $121,954,153,095,664, and the highest ABBV revenue forecast at $137,874,746,879,712.
In 2028, ABBV is forecast to generate $140,237,020,679,744 in revenue, with the lowest revenue forecast at $124,830,964,078,188 and the highest revenue forecast at $150,075,113,062,512.